Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2018 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS

LA JOLLA, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 19, 2018 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan

LA JOLLA, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
May 09, 2018 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma

LA JOLLA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
May 08, 2018 19:00 ET | Source: MediciNova, Inc.

MediciNova to Present at the UBS Global Healthcare Conference in New York

LA JOLLA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
May 07, 2018 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal

LA JOLLA, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 26, 2018 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting

LA JOLLA, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 24, 2018 06:30 ET | Source: MediciNova, Inc.

MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data

LA JOLLA, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 13, 2018 06:30 ET | Source: MediciNova, Inc.

MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France

LA JOLLA, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
April 01, 2018 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis

LA JOLLA, Calif., April 01, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 29, 2018 06:30 ET | Source: MediciNova, Inc.

MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence

LA JOLLA, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...